[{"id":"9c4a2f2e-02e2-4323-b07b-9db19cb9e3c7","acronym":"NCI-2018-01137","url":"https://clinicaltrials.gov/study/NCT03604315","created_at":"2021-01-18T17:43:10.075Z","updated_at":"2024-07-02T16:35:11.528Z","phase":"Phase 1","brief_title":"Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF","source_id_and_acronym":"NCT03604315 - NCI-2018-01137","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation • PARP1 mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation • PARP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 12/18/2018","start_date":" 12/18/2018","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-04-03"},{"id":"a918b622-1695-4ae4-8aaf-74e22d538627","acronym":"","url":"https://clinicaltrials.gov/study/NCT05746728","created_at":"2023-02-28T13:01:14.764Z","updated_at":"2024-07-02T16:35:51.316Z","phase":"Phase 1/2","brief_title":"Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer","source_id_and_acronym":"NCT05746728","lead_sponsor":"Huihua Xiong","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 expression • ER expression • PARP1 mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • ER expression • PARP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Sulanda (surufatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-04-06"},{"id":"2d2151b9-bb9d-4b8d-930f-541ba1b161c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05458973","created_at":"2022-07-14T13:54:31.140Z","updated_at":"2024-07-02T16:36:04.072Z","phase":"","brief_title":"Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.","source_id_and_acronym":"NCT05458973","lead_sponsor":"Yonsei University","biomarkers":" BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation • PARP1 mutation","tags":["BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation • PARP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-09-13"}]